NEW YORK (GenomeWeb News) – RainDance Technologies said this week that it has made the first commercial shipment of its RDT 1000 and Sequence Enrichment Solution. The Lexington, Mass.-based firm said that it had shipped the RDT 1000, consumables kits, and custom PCR prime libraries to the Ontario Institute for cancer Research, which will use the products in its discovery and validation of DNA sequence variants associated with cancers.
Thermo Fisher Scientific announced that the University of Middlesex in Hendon, UK, is using its Verso cDNA Synthesis Kit and Absolute Blue QPCR Master Mix in its cancer biomarker research projects.
Celera presented a poster at this week's American College of Medical Genetics meeting in Tampa, Fla., on its prototype Fragile X screening assay. According to the firm, and collaborators from the University of Utah and ARUP Laboratories, the assay "was found to detect expanded alleles in all pre-mutation and full mutation patients with 100 percent sensitivity in both genders, in addition to identifying all non-expanded alleles in patients with 100 percent specificity."
In Brief This Week is a new Friday column containing news items that our readers may have missed during the week.